

CLAIMS

What is claimed is:

1. A method for the preventative treatment migraine in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof.
2. The method of Claim 1, wherein administering the pharmaceutical composition provides a reduction in the mean number of migraine days per month for said patient.
3. The method of Claim 1, wherein the pharmaceutical composition is administered at least once every other day.
4. The method of Claim 2, wherein the reduction in the mean number of migraine days per month for said patient at least 20%.
5. The method of Claim 2, wherein the reduction in the mean number of migraine days per month for said patient at least 30%.
6. The method of claim 2, wherein the reduction in the mean number of migraine days per month for said patient at least 40%.
7. The method of Claim 2, wherein the reduction in the mean number of migraine days per month for said patient at least 50%.
8. The method of Claim 3, wherein the pharmaceutical composition is administered once every other day.
9. The method of claim 3, wherein the pharmaceutical composition is administered not more than once per day.

10. The method of Claim 1, wherein the patient is also administered a medication for the treatment of acute migraine.
11. The method of Claim 10, wherein the medication is a CGRP inhibitor selected from a CGRP antibody, a CGRP receptor antibody, an antigen-binding fragment from a CGRP antibody or a CGRP receptor antibody, a CGRP infusion inhibitory protein, a CGRP bio-neutralizing agent, a CGRP receptor antagonist, a small molecule CGRP inhibitor, or a polypeptide CGRP inhibitor.
12. The method of Claim 11, wherein the CGRP antibody is selected from galcanezumab-gnlm, fremanezumab-vfrm, eptinezumab-jjmr, and erenumab-aooe.
13. The method of Claim 11, wherein the CGRP receptor antagonist is selected from olcegepant, telcagepant, ubrogepant, atogepant, rimegepant, and zavegepant.
14. The method of Claim 1, wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt.
15. The method of Claim 1, wherein the pharmaceutical composition is in the form of a tablet.
16. The method of claim 15, wherein the pharmaceutical composition comprises from about 50-60 weight% rimegepant hemisulfate sesquihydrate, about 30-35 weight% microcrystalline cellulose, about 2-7 weight% hydroxypropyl cellulose, about 3-7 weight% croscarmellose sodium, and about 0.1-1.0 weight% magnesium stearate.
17. The method of Claim 16, wherein the pharmaceutical composition comprises about 57.1 weight% rimegepant hemisulfate sesquihydrate, about 33.4 weight% microcrystalline cellulose, about 4.0 weight% hydroxypropyl cellulose, about 5.0 weight% croscarmellose sodium, and about 0.5 weight% magnesium stearate.
18. The method of Claim 1, wherein the pharmaceutical composition is in the form of an oral solid molded fast-dispersing dosage form.

19. The method of Claim 18, wherein the pharmaceutical composition comprises from about 70-80 weight% rimegepant hemisulfate sesquihydrate, about 10-20 weight% fish gelatin, about 10-20 weight% of a filler, and 0.1-5.0 weight% of a flavorant.
20. The method of Claim 19, wherein the filler is mannitol.
21. A method of treating sinusitis in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof, in order to relieve a symptom associated with the sinusitis.
22. The method of Claim 21, wherein the treatment is effective to provide pain relief to the patient.
23. The method of Claim 21, wherein the treatment is effective to reduce an infection in the patient.
24. The method of Claim 21, wherein the treatment is effective to reduce inflammation in the patient.